ZTS
ZoetisNYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-05-08
As of May 8, 2026, ZTS has a composite score of 15.6 and a signal label of "mild_favorable." The valuation score increased significantly by 20.2 points to 74.0, while total stock risk rose by 12.5 points to 50.5. The valuation label changed from "fair" to "inexpensive" following fresh earnings. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.06
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.90 → $1.90 (-0.3% / 30d). 0 raised, 5 cut, 15 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 62% of analysts rate Buy.
3 PT revisions / 30d. Avg target 16.8% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
1 material event in the last 24 months — top 1 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Revenue growth guidance for 2026growthbehind0% progress
5/7: “Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion.”
Why this status
Stated in 2 of last 2 quarters. Revenue guidance for 2026 was revised from $9.825-$10.025B to $9.680-$9.960B, indicating a downward adjustment. The financials show revenue of $2.206B in 2025-Q4, down from $2.4B in 2025-Q3, suggesting limited progress towards the higher end of the guidance range.
- 2.EPS guidance for 2026growthbehind0% progress
5/7: “Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00.”
Why this status
Stated in 2 of last 2 quarters. EPS guidance for 2026 was revised upward from $6.65-$6.75 to $6.85-$7.00. The financials show diluted EPS of 1.63 in 2025-Q3, indicating some progress towards the revised guidance, but the trajectory remains uncertain given the earnings miss in 2026-Q1.
- 3.Dividend update for 2026capital allocationmixed36% progressprovisional
2/5: “Declared a dividend of $0.53 per share for the second quarter of 2026.”
Why this status
Newly stated in 2026-Q1. Zoetis declared a dividend of $0.53 per share for 2026-Q2, reflecting a commitment to return capital to shareholders. This follows a dividend of $0.5 in 2025-Q2, indicating a modest increase. The financials show stable cash from operations, supporting this allocation.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 76%; 252d 37%.
Drawdown — Max 1y −51%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.85 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 39/100, drawdown 0/100, beta 85/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · valuation_scoreseverity 40
Valuation rose by 20.2 points (from 53.8 to 74.0).
- risk change · total_stock_risk_scoreseverity 25
Total stock risk rose by 12.5 points (from 38.0 to 50.5).
- risk change · market_risk_scoreseverity 21
Market risk rose by 12.5 points (from 38.0 to 50.5).
- earnings refresh · signal_labelseverity 20
Signal changed from 'mixed' to 'mild_favorable' after fresh earnings.
- label change · valuation_labelseverity 20
Valuation label changed from 'fair' to 'inexpensive'.
As of May 8, 2026, ZTS experienced several notable changes. The valuation score rose by 20.2 points, increasing from 53.8 to 74.0, and the valuation label changed from 'fair' to 'inexpensive'. However, total stock risk and market risk both rose by 12.5 points, now at 50.5. Additionally, the signal label transitioned from 'mixed' to 'mild_favorable' following fresh earnings.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Revenue growth guidance for 2026
GrowthNew since 2026-05-07Zoetis has revised its full year 2026 revenue guidance to $9.680 - $9.960 billion.
BehindStated in 2 of last 2 quarters. Revenue guidance for 2026 was revised from $9.825-$10.025B to $9.680-$9.960B, indicating a downward adjustment. The financials show revenue of $2.206B in 2025-Q4, down from $2.4B in 2025-Q3, suggesting limited progress towards the higher end of the guidance range.
Revenue guidance revised from $9.825-$10.025B to $9.680-$9.960B0%CEO/CFO:“Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion.”Multiple sourcesSource dated 2026-05-07Stated 2 of last 8 quartersFirst seen 2026-05-07Show history (2)
- 2026-Q1Multiple sources
“Provides Full Year 2026 Revenue Guidance of $9.825 - $10.025 Billion.”
- 2025-Q4Multiple sources
“Revises Full Year 2026 Revenue Guidance to $9.680 - $9.960 Billion.”
- #2
EPS guidance for 2026
GrowthNew since 2026-05-07Zoetis revised its guidance for diluted EPS on an adjusted basis to $6.85 to $7.00 for 2026.
BehindStated in 2 of last 2 quarters. EPS guidance for 2026 was revised upward from $6.65-$6.75 to $6.85-$7.00. The financials show diluted EPS of 1.63 in 2025-Q3, indicating some progress towards the revised guidance, but the trajectory remains uncertain given the earnings miss in 2026-Q1.
EPS guidance revised from $6.65-$6.75 to $6.85-$7.000%CEO/CFO:“Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00.”Multiple sourcesSource dated 2026-05-07Stated 2 of last 8 quartersFirst seen 2026-05-07Show history (2)
- 2026-Q1Multiple sources
“Reported diluted EPS between $6.65 to $6.75.”
- 2025-Q4Multiple sources
“Revises Guidance for Diluted EPS on an Adjusted Basis to $6.85 to $7.00.”
- #3
Dividend update for 2026
Capital allocationZoetis declared a dividend of $0.53 per share for the second quarter of 2026.
MixedNewly stated in 2026-Q1. Zoetis declared a dividend of $0.53 per share for 2026-Q2, reflecting a commitment to return capital to shareholders. This follows a dividend of $0.5 in 2025-Q2, indicating a modest increase. The financials show stable cash from operations, supporting this allocation.
36%CEO/CFO:“Declared a dividend of $0.53 per share for the second quarter of 2026.”Multiple sourcesSource dated 2026-02-05Stated 1 of last 8 quartersFirst seen 2026-02-05provisionalShow history (1)
- 2026-Q1Multiple sources
“Declared a dividend of $0.53 per share for the second quarter of 2026.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
ZTS Zoetis | +16 | inexpensive | elevated |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-05-07)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-05-07)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-071d agoItem 2.02
and the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
earnings preannouncementnegativescore 77 - 2026-02-122mo agoItem 2.02
and in the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
earnings preannouncementneutralscore 9 - 2026-02-053mo agoItem 7.01
Regulation FD Disclosure. On February 5, 2026, the Company declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on June 2, 2026, to all holders of record of the Company’s common stock as of the close of business on April 20, 2026. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Secu…
capital allocationneutralscore 6
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.